This inventor holds 4 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: University of California, Shinshu University, Other. Active years: 2017-2026.
Location History:
- Los Angeles, CA (US) (2017 - 2018)
- Irvine, CA (US) (2021)
Company Filing History:
3 out of 15,964 
1 out of 128 
1 out of 834,307 Years Active: 2017-2026
Title: Ichiro Yuki: Innovator in Liquid Embolic Agent Composition
Introduction
Ichiro Yuki is a notable inventor based in Irvine, California. He has made significant contributions to the field of medical technology, particularly in the development of liquid embolic agents. His innovative work addresses critical challenges in treating vascular diseases, such as cerebral aneurysms.
Latest Patents
Ichiro Yuki holds a patent for a liquid embolic agent composition. This composition is designed to overcome the limitations of conventional embolic agents. It features a hydrogel forming component that has the ability to entrap calcium ions, along with an anti-biodegradation component. The hydrogel forming component includes acidic polysaccharides like alginate, gellan gum, carrageenan, and carboxymethyl cellulose salt. The anti-biodegradation component consists of materials such as hydroxypropyl methylcellulose, methylcellulose, polyvinyl alcohol, polyallylamine, poly-N-vinyl acetamide, and cellulose acetate. This innovative composition aims to enhance the effectiveness of treatments for vascular diseases.
Career Highlights
Throughout his career, Ichiro Yuki has worked at Shinshu University, where he has contributed to various research projects. His expertise in the field of medical technology has positioned him as a valuable asset in the development of advanced medical solutions.
Collaborations
Ichiro Yuki has collaborated with notable colleagues, including Kousaku Ohkawa and Takaomi Nomura. These partnerships have fostered innovation and have been instrumental in advancing research in the medical field.
Conclusion
Ichiro Yuki's contributions to the development of liquid embolic agents represent a significant advancement in medical technology. His innovative approach addresses critical issues in treating vascular diseases, showcasing his dedication to improving patient outcomes.